270 related articles for article (PubMed ID: 9918197)
21. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
Edwards BS; Hawkins MJ; Borden EC
Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
[TBL] [Abstract][Full Text] [Related]
22. Immunological consequences of interleukin 12 administration after autologous stem cell transplantation.
Pelloso D; Cyran K; Timmons L; Williams BT; Robertson MJ
Clin Cancer Res; 2004 Mar; 10(6):1935-42. PubMed ID: 15041709
[TBL] [Abstract][Full Text] [Related]
23. [Interferon therapy effects on activation of T-lymphocytes in patients with systemic lupus erythematosus].
Stanislav ML; Balabanova RM; Nikonova MF; Litvina MM; Iarilin AA
Ter Arkh; 2000; 72(5):44-9. PubMed ID: 11109620
[TBL] [Abstract][Full Text] [Related]
24. Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity.
Meropol NJ; Porter M; Blumenson LE; Lindemann MJ; Perez RP; Vaickus L; Loewen GM; Creaven PJ; Wilkes KA; Giedlin MA; Caligiuri MA
Clin Cancer Res; 1996 Apr; 2(4):669-77. PubMed ID: 9816217
[TBL] [Abstract][Full Text] [Related]
25. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
26. Suppression of natural killer cell cytotoxicity in the peripheral blood of patients receiving interferon therapy.
Spina CA; Fahey JL; Durkos-Smith D; Dorey F; Sarna G
J Biol Response Mod; 1983; 2(5):458-69. PubMed ID: 6644350
[TBL] [Abstract][Full Text] [Related]
27. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.
Fehniger TA; Shah MH; Turner MJ; VanDeusen JB; Whitman SP; Cooper MA; Suzuki K; Wechser M; Goodsaid F; Caligiuri MA
J Immunol; 1999 Apr; 162(8):4511-20. PubMed ID: 10201989
[TBL] [Abstract][Full Text] [Related]
28. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma.
Bajorin DF; Chapman PB; Wong G; Coit DG; Kunicka J; Dimaggio J; Cordon-Cardo C; Urmacher C; Dantes L; Templeton MA
Cancer Res; 1990 Dec; 50(23):7490-5. PubMed ID: 2253196
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of different effects of sera of breast cancer patients on the activity of natural killer cells.
Konjević G; Spuzić I
J Clin Lab Immunol; 1992; 38(2):83-93. PubMed ID: 1343351
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.
Kolitz JE; Wong GY; Welte K; Merluzzi VJ; Engert A; Bialas T; Polivka A; Bradley EC; Konrad M; Gnecco C
J Biol Response Mod; 1988 Oct; 7(5):457-72. PubMed ID: 3263471
[TBL] [Abstract][Full Text] [Related]
31. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of IL-18 receptor in cancer patients: its clinical significance.
Kobashi K; Iwagaki H; Yoshino T; Morimoto Y; Kohka H; Kodama M; Nishibori M; Akagi T; Tanaka N
Anticancer Res; 2001; 21(5):3285-93. PubMed ID: 11848485
[TBL] [Abstract][Full Text] [Related]
33. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer.
Urba WJ; Steis RG; Longo DL; Kopp WC; Maluish AE; Marcon L; Nelson DL; Stevenson HC; Clark JW
Cancer Res; 1990 Jan; 50(1):185-92. PubMed ID: 2293554
[TBL] [Abstract][Full Text] [Related]
34. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides.
Duvic M; Sherman ML; Wood GS; Kuzel TM; Olsen E; Foss F; Laliberté RJ; Ryan JL; Zonno K; Rook AH
J Am Acad Dermatol; 2006 Nov; 55(5):807-13. PubMed ID: 17052486
[TBL] [Abstract][Full Text] [Related]
35. An in vitro Shwartzman reaction-like response is augmented age-dependently in human peripheral blood mononuclear cells.
Motegi A; Kinoshita M; Sato K; Shinomiya N; Ono S; Nonoyama S; Hiraide H; Seki S
J Leukoc Biol; 2006 Mar; 79(3):463-72. PubMed ID: 16387840
[TBL] [Abstract][Full Text] [Related]
36. Heat shock suppresses human NK cell cytotoxicity via regulation of perforin.
Harada H; Murakami T; Tea SS; Takeuchi A; Koga T; Okada S; Suico MA; Shuto T; Kai H
Int J Hyperthermia; 2007 Dec; 23(8):657-65. PubMed ID: 18097852
[TBL] [Abstract][Full Text] [Related]
37. [Subsets of peripheral blood lymphocytes and tumor infiltrating lymphocytes in cancer patients received chemotherapy].
Mitachi Y; Murakawa Y; Okuno M; Kambe M; Kanamaru R; Takahasi H; Wakui A
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):482-8. PubMed ID: 2138871
[TBL] [Abstract][Full Text] [Related]
38. Regulation of human natural killer cell cytotoxicity by recombinant leukocyte interferon clone A.
Lotzová E; Savary CA; Gutterman JU; Quesada JR; Hersh EM
J Biol Response Mod; 1983; 2(5):482-96. PubMed ID: 6644351
[TBL] [Abstract][Full Text] [Related]
39. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin.
Batoni G; Esin S; Favilli F; Pardini M; Bottai D; Maisetta G; Florio W; Campa M
Scand J Immunol; 2005 Dec; 62(6):498-506. PubMed ID: 16316416
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
Lenzi R; Rosenblum M; Verschraegen C; Kudelka AP; Kavanagh JJ; Hicks ME; Lang EA; Nash MA; Levy LB; Garcia ME; Platsoucas CD; Abbruzzese JL; Freedman RS
Clin Cancer Res; 2002 Dec; 8(12):3686-95. PubMed ID: 12473577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
